Cresco Labs (OTCMKTS:CRLBF) Releases Earnings Results, Misses Expectations By $0.02 EPS

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.02), Zacks reports. The business had revenue of $165.00 million during the quarter, compared to analyst estimates of $163.74 million. Cresco Labs had a negative return on equity of 11.77% and a negative net margin of 6.67%.Cresco Labs Price PerformanceOTCMKTS:CRLBF opened at $1.07 on Friday. The stock has a market capitalization of $380.85 million, a PE ratio of -7.13 and a beta of 1.51. Cresco Labs has a 1-year low of $0.43 and a 1-year high of $1.62. The firm has a fifty day simple moving average of $1.21 and a 200 day simple moving average of $0.89. The company has a current ratio of 3.10, a quick ratio of 2.22 and a debt-to-equity ratio of 1.33. Wall Street Analyst Weigh InSeparately, Zacks Research cut shares of Cresco Labs from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold".Get Our Latest Stock Report on CRLBFAbout Cresco Labs (Get Free Report)Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.Further ReadingFive stocks we like better than Cresco LabsA Deeper Look at Bid-Ask SpreadsRivian’s Chart Says Go, But Some Analysts Still Say NoInvesting in Travel Stocks Benefitse.l.f. Sell-Off Is a Good Time to Buy, According to AnalystsFind and Profitably Trade Stocks at 52-Week LowsT-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Cresco Labs Right Now?Before you consider Cresco Labs, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.While Cresco Labs currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here